© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
January 19, 2021
The investigational padeliporfin ImPACT platform involves the intravenous delivery of the photosensitive drug padeliporfin, which is then activated by a non-thermal light delivery system.
January 13, 2021
The collaboration will focus on the novel combinatorial intravesical immunotherapy UGN-302 as a potential treatment for patients with high-grade non-muscle invasive bladder cancer.
January 12, 2021
Disease stage and adverse features were the main predictors of relapses and survival after robot-assisted radical cystectomy.
Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.
January 11, 2021
Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.
The approval was based on findings from the phase 3 JAVELIN Bladder 100 study.
January 06, 2021
Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.
The combination of eganelisib and nivolumab demonstrated promising activity and was well tolerated in a phase 2 trial of patients with advanced urothelial cancer.
December 25, 2020
The paper is meant to serve as a single source of information for helping patients with bladder cancer.
December 21, 2020
Combining the novel interleukin-15 superagonist complex N-803 (Anktiva) with BCG led to a high complete response rate in patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.
December 16, 2020
Gomella looks back on the year's top headlines in bladder cancer, from FDA approvals to notable clinical trial results.
December 15, 2020
Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.
December 14, 2020
The PD-L1 inhibitor has been recommended for approval in this setting based on data from the phase 3 JAVELIN Bladder 100 study.
December 10, 2020
The phase 2 study has a targeted enrollment of 37 patients and a primary end point of complete response.
December 09, 2020
Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.
November 30, 2020
“These data published in the Lancet Oncology show that nadofaragene firadenovec, a first-of-its-kind therapy, may be an effective treatment option for BCG-unresponsive non-muscle invasive bladder cancer patients,” Colin P. N. Dinney, MD.
November 24, 2020
Improvement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
November 20, 2020
The new fixed-dose schedule is approved for all of durvalumab's FDA indications, including advanced bladder cancer.
November 17, 2020
UGN-102 (mitomycin) for intravesical solution induced long-lasting complete responses in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
November 11, 2020
Scott T. Tagawa, MD, highlighted pivotal data for enfortumab vedotin and sacituzumab govitecan at the 38th Annual CFS meeting.